Page 1

In the News December 13th , 2021 ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022 VICTORIA , BRITISH COLUMBIA December 13 , 2021 / - IMMUNOPRECISE ANTIBODIES LTD . ( the " Company " or " IPA " ) ( NASDAQ : IPA ) ( TSX VENTURE : IPA ) , a leader in full - service therapeutic antibody discovery and development , today announced financial results for second quarter fiscal year 2022 , which ended October 31 , 2021 . Second Quarter Fiscal Year 2022 Financial Summary * • The Company achieved revenues of $ 4.7 million , a decrease of $ 32,780 or ( 0.7 % ) from the same period last year ** . • The Company , primarily through its subsidiary Talem Therapeutics LLC , invested $ 2.8 million in strategic research and development costs compared to $ 1.1 million in the same period last year . • The Company recorded a net loss of $ 5.0 million during the three months ended October 31 , 2021 , compared to net loss of $ 463,584 for the three months ended October 31 , 2020 . • Adjusted EBITDA *** was a loss of $ 2.9 million , as compared to positive EBITDA of $ 795,159 for the same period last year . • As of October 31 , 2021 , the Company held cash of $ 38.4 million * Expressed in Canadian dollars , unless otherwise indicated . ** Please see section titled Revenue below for additional information on stated revenue in fiscal year